Remedy (REMEDY) Q2 2026 earnings summary

Executive summary

• Q2 2026 revenue declined 40% year-over-year to EUR 10.2 million, mainly due to the absence of prior year launch-related revenues and increased marketing for CONTROL Resonant.

• EBITDA was EUR -2.4 million and EBIT EUR -3.9 million, reflecting higher marketing and personnel expenses.

• CONTROL Resonant, launching globally on September 24, 2026, saw significant marketing ramp-up, over 1.5 million wishlists, and strong early commercial indicators.

• Alan Wake 2 surpassed three million lifetime copies sold; Control reached over six million copies and more than 20 million lifetime players, with year-over-year growth in Q2.

• CEO Jean-Charles Gaudechon was appointed in March 2026.

Financial highlights

• Q2 2026 revenue was EUR 10.2 million, a 40% decrease from the prior year; H1 2026 revenue was EUR 23.3 million, down 23.1% year-over-year.

• EBITDA for Q2 was EUR -2.4 million (vs. EUR 4.2 million prior year); H1 EBITDA was EUR 0.5 million (vs. EUR 6.8 million prior year).

• EBIT for Q2 was EUR -3.9 million; H1 EBIT was EUR -2.9 million.

• Cash and liquid investments at end of June 2026 totaled EUR 29.6 million.

• Q2 cash flow from operations was EUR -0.7 million; H1 cash flow from operations was EUR 7.6 million.

Outlook and guidance

• Full-year 2026 revenue and EBITDA are expected to increase from 2025, with guidance unchanged.

• Profitability for 2026 will depend on CONTROL Resonant’s sales performance.

• Long-term targets include doubling 2024 revenue by 2027 and achieving a 30% EBITDA margin by 2027.

• Marketing expenses are expected to peak around the CONTROL Resonant launch window.